The Cooper Companies (COO)
(Real Time Quote from BATS)
$106.57 USD
+0.07 (0.07%)
Updated Sep 6, 2024 03:50 PM ET
After-Market: $106.55 -0.02 (-0.02%) 4:14 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.57 USD
+0.07 (0.07%)
Updated Sep 6, 2024 03:50 PM ET
After-Market: $106.55 -0.02 (-0.02%) 4:14 PM ET
2-Buy of 5 2
C Value D Growth B Momentum D VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -60.47% and 2.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Lags Q4 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -3.80% and 3.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Conmed (CNMD) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 12.90% and 2.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Company News for Mar 7, 2022
by Zacks Equity Research
Companies in The News Are: AVGO,CO,ESTC,PWSC
Cooper Companies (COO) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.
The Cooper Companies (COO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 5.19% and 6.84%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
Patterson Cos. (PDCO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 10% and 1.82%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Why The Cooper Companies (COO) Might Surprise This Earnings Season
by Zacks Equity Research
The Cooper Companies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Greif (GEF) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Greif's (GEF) Q1 performance is likely to reflect benefits from strong volume growth across key end-markets, robust packaging demand and cost-control actions.
3 Medical Device Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
The Medical device companies' Q4 results are likely to reflect base business recovery on a year-over-year basis. Let's see how PRGO, COO and SGHT are poised ahead of their earnings releases.
The Cooper Companies (COO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
The Cooper Companies (COO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Becton Dickinson (BDX) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 27.27% and 4.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AmerisourceBergen (ABC) Misses Q1 Earnings Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of -0.39% and 0.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HSIC vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. COO: Which Stock Is the Better Value Option?
Cooper Companies (COO) Q4 Earnings Lag Estimates, Margins Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.
The Cooper Companies (COO) Q4 Earnings Lag Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -2.67% and 1.52%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
The Cooper Companies (COO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LH vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. COO: Which Stock Is the Better Value Option?
Cooper Companies' (COO) Buyout to Boost Women's Healthcare
by Zacks Equity Research
Cooper Companies' (COO) agrees to acquire Generate Life Sciences. It will be an important addition to the former's present offerings, while improving women's healthcare.